Manufacturing issues hobble Heron’s quest to market its long-acting non-opioid painkiller

The C-suite at Pacira likely sighed in relief on Wednesday, as their main rival, Heron Therapeutics, was handed an unexpected FDA rejection — related to manufacturing concerns — for a competing long-acting non-opioid painkiller for post-surgical analgesia.